Zobrazeno 1 - 6
of 6
pro vyhledávání: '"ZUNHAI ZHOU"'
Autor:
Jianlin Geng, Xuejun Li, Zhiqiang Ning, Haixiang Cao, Weihong Song, Xin Gao, Zunhai Zhou, Yangang Wang, He Yao, Hanqing Cai, Lian Guo, Wei Li, Xinsheng Li, Gangyi Yang, Zhiguang Zhou, Desi Pan, Fuyan Shi, Hongmei Li, Weiping Jia, Yanjun Liu, Linong Ji, Hui Fang, Haoming Tian, Shuying Li, Yancheng Xu, Qifu Li, Kuanzhi Liu, Lu Xianping, Tao Yang, Qiuhe Ji, Qing Su, Wenbo Wang
Publikováno v:
Science Bulletin. 66:1571-1580
Chiglitazar (Carfloglitazar) is a novel non-thiazolidinedione (TZD) structured peroxisome proliferator-activated receptor (PPAR) pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::275485429bd15a01ce729a6280acb071
https://doi.org/10.1016/j.scib.2021.03.019
https://doi.org/10.1016/j.scib.2021.03.019
Autor:
Wenhui Li, Jianhua Ma, Jingna Lin, Tao Yang, Wenlong Jin, Wei Qiu, Guixia Wang, Lijun Liu, Hui Liu, Xiaoying Li, Xiaolin Dong, Hongwei Jiang, Dalong Zhu, Shen Qu, Yongqian Liang, Zhou Yang, Weihong Song, Junping Su, Shenglian Gan, Yibing Lu, Chenzhong Li, W. G. Li, Zhaoshun Jiang, Jialin Gao, Song Dong, Hongmei Li, Xiaoqiang Fei, Zhenmei An, Huiwen Tan, Yu Zhao, Minxiu Yao, Hong Mao, Qing Su, Guoyue Yuan, Li Chen, Xuefeng Li, Zunhai Zhou, Tianfeng Wu, Qi Yao, Xiaomei Zhang, Lixin Shi, Jiao’e Zeng, Zhongyan Shan, Bo Feng, Song Lu, Qiu Zhang, Ping Liu, Huifang Li, Feng Li, Xiuzhen Zhang, Wenying Yang, Kuanlu Fan, Ziling Li, Daoxiong Chen, Shandong Ye, Xiaohui Guo, Xiaozhen Jiang, Ruonan Li, Jiao Sun, Yufeng Li, Wenbo Wang, Wenjuan Zhao, Yulan Li, Wen Hu, Ying Zhao, Dong Zhao, Jingdong Liu, Zhinong Zhang, Yongli Yao, Liling Tan, Xiaoyue Wang, Yaoming Xue, Weiping Lu, Tao Ning, Huili Zhang, Yi Zhang
Metformin is the first-line therapy for the treatment of type 2 diabetes (T2D) through mechanism of reduction in hepatic glucose production and fasting plasma glucose. Dorzagliatin is a novel glucokinase activator (GKA) that improves glucose and insu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea2cfe632866c2ee2d63cf12d7e95173
https://doi.org/10.21203/rs.3.rs-733332/v1
https://doi.org/10.21203/rs.3.rs-733332/v1
Autor:
Wenying Yang, Dalong Zhu, Shenglian Gan, Xiaolin Dong, Junping Su, Wenhui Li, Hongwei Jiang, Wenjuan Zhao, Minxiu Yao, Weihong Song, Yibing Lu, Xiuzhen Zhang, Huifang Li, Guixia Wang, Wei Qiu, Guoyue Yuan, Jianhua Ma, Wei Li, Ziling Li, Xiaoyue Wang, Jiao’e Zeng, Zhou Yang, Jingdong Liu, Yongqian Liang, Song Lu, Huili Zhang, Hui Liu, Ping Liu, Kuanlu Fan, Xiaozhen Jiang, Yufeng Li, Qing Su, Tao Ning, Huiwen Tan, Zhenmei An, Zhaoshun Jiang, Lijun Liu, Zunhai Zhou, Qiu Zhang, Xuefeng Li, Zhongyan Shan, Yaoming Xue, Hong Mao, Lixin Shi, Shandong Ye, Xiaomei Zhang, Jiao Sun, Ping Li, Tao Yang, Feng Li, Jingna Lin, Zhinong Zhang, Ying Zhao, Ruonan Li, Xiaohui Guo, Qi Yao, Weiping Lu, Shen Qu, Hongmei Li, Liling Tan, Wenbo Wang, Yongli Yao, Daoxiong Chen, Yulan Li, Jialin Gao, Wen Hu, Xiaoqiang Fei, Tianfeng Wu, Song Dong, Wenlong Jin, Chenzhong Li, Dong Zhao, Bo Feng, Yu Zhao, Yi Zhang, Xiaoying Li, Li Chen
Publikováno v:
Nature medicine. 28(5)
Metformin, the first-line therapy for type 2 diabetes (T2D), decreases hepatic glucose production and reduces fasting plasma glucose levels. Dorzagliatin, a dual-acting orally bioavailable glucokinase activator targeting both the pancreas and liver g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9949cd2f98ee9b986ae5c6880f0d27a3
https://pubmed.ncbi.nlm.nih.gov/35551293
https://pubmed.ncbi.nlm.nih.gov/35551293
Publikováno v:
Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 70(5)
FOXO3a is a widely studied transcription factor and plays an important role in a variety of biology. The purpose of this study was to explore the role and potential mechanism of FOXO3a on lipid accumulation and adipocyte inflammation in adipocytes th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::366cbf02bfd9307cedb6ebf2672cd50a
https://pubmed.ncbi.nlm.nih.gov/33891136
https://pubmed.ncbi.nlm.nih.gov/33891136
Autor:
LINONG JI, WEIHONG SONG, HUI FANG, WEI LI, JIANLIN GENG, YAN CHENG XU, YANGANG WANG, LIAN GUO, HANQING CAI, TAO YANG, HONG-MEI LI, GANGYI YANG, QIFU LI, KUANZHI LIU, SHUYING LI, YANJUN LIU, FUYAN SHI, XIN SHENG LI, XIN GAO, QIUHE JI, HAOMING TIAN, QING SU, ZHIGUANG ZHOU, WENBO WANG, ZUNHAI ZHOU, XUEJUN LI, ZHIQIANG NING, XIANPING LU, WEIPING JIA
Publikováno v:
Diabetes. 68
Chiglitazar showed favorable effect on glycemic control and lipid modulation with well tolerated safety profile in phase 2 trials. This trial aimed to further compare the efficacy and safety of chiglitazar with placebo in patients with type 2 diabete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e256f6fa60efc150869d41861b072c6a
https://doi.org/10.2337/db19-17-or
https://doi.org/10.2337/db19-17-or
Autor:
Shuying Li, Desi Pan, Fuyan Shi, Jianlin Geng, Lian Guo, Xin Gao, Yangang Wang, He Yao, Yanjun Liu, Xuejun Li, Weihong Song, Hanqing Cai, Gangyi Yang, Kuanzhi Liu, Zhiqiang Ning, Yancheng Xu, Qiuhe Ji, Qing Su, Hui Fang, Zunhai Zhou, Wenbo Wang, Linong Ji, Wei Li, Qifu Li, Tao Yang, Haixiang Cao, Xinsheng Li, Zhiguang Zhou, Weiping Jia, Haoming Tian, Hongmei Li, Xianping Lu
Publikováno v:
SSRN Electronic Journal.
Background: Chiglitazar is a novel PPARα/γ/δ pan-agonist with moderate transcriptional activities. Phase 2 studies demonstrated that chiglitazar had significant effects on glycemic control and lipid modulation in patients with type 2 diabetes. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42e2c2fcb8e8ebe0f13ea086b99ea93d
https://doi.org/10.2139/ssrn.3437798
https://doi.org/10.2139/ssrn.3437798